Ocugen, Inc. today announced it will be featured as a presenting company at the 19th Annual Rodman & Renshaw Global Investment Conference.
FDA Decision Marks First Orphan Drug Designation for Treatment of oGVHD in the U.S.
Company Strengthens Board with Three Key Director Appointments
Funds to be Used to Advance Clinical Pipeline
Company Receives Patents in US and Japan and Notice of Intent to Grant Patent in EU
Funding Clears Path for OCU300 Investigational New Drug (IND) Application
Announces License Agreement with University of Illinois at Chicago (UIC) for OCU300; Patent Allowed for OCU200, Novel, Preclinical Biologic in Development for Wet AMD
Company Announces Executive Management, Board and Scientific Advisory Board Updates
Start-up Ocugen eyes new ophthalmology opportunities.
Licensed Two Biological Drug Candidates from University of Colorado.